Abstract
We have constructed a novel oncolytic adenovirus (Ad) vector, named VRX-011, in which the replication of the vector is targeted to cancer cells by the replacement of the wild-type Ad E4 promoter with the human telomerase reverse transcriptase (hTERT) promoter. Genes in the Ad E4 transcription unit are essential for Ad replication; therefore, VRX-011 will grow efficiently only in cells in which the hTERT promoter is active, that is, in a wide range of cancer and immortalized cells but not in most somatic cells. Consistent with these expectations, VRX-011 replicated efficiently in all cancer cell lines examined, while its growth was restricted in various primary and normal cells. VRX-011 overexpresses ADP (also known as E3-11.6K), an Ad protein required for efficient cell lysis and release of virions from cells at late stages of infection. This overexpression enhances cell-to-cell spread and could significantly increase antitumor efficacy. In a xenograft model in nude mice, both intratumoral and intravenous administration of VRX-011 effectively suppressed the growth of subcutaneous Hep3B human liver tumors. Also, intravenous delivery of VRX-011 greatly reduced the number and size of A549 human lung cancer cell nodules in a disseminated lung tumor model in nude mice. Importantly, tail vein administration of different doses of VRX-011 in C57BL/6 mice showed minimal liver toxicity. Considering its broad range of lytic replication in cancer cells, its attenuated phenotype in primary cells, its efficacy in suppressing xenografts, and its low toxicity in mouse liver, VRX-011 is a promising candidate for further evaluation as an anticancer therapeutic.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Russell WC . Update on adenovirus and its vectors. J Gen Virol 2000; 81: 2573–2604.
Kanerva A, Hemminki A . Modified adenoviruses for cancer gene therapy. Int J Cancer 2004; 110: 475–480.
Oosterhoff D, Van Beusechem VW . Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy. J Exp Ther Oncol 2004; 4: 37–57.
Kirn D, Martuza RL, Zwiebel J . Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781–787.
Haviv YS, Curiel DT . Engineering regulatory elements for conditionally-replicative adeno-viruses. Curr Gene Ther 2003; 3: 357–385.
Dobbelstein M . Replicating adenoviruses in cancer therapy. Curr Top Microbiol Immunol 2004; 273: 291–334.
Babiss LE, Friedman JM, Darnell Jr JE . Cellular promoters incorporated into the adenovirus genome. Effect of viral DNA replication on endogenous and exogenous gene transcription. J Mol Biol 1987; 193: 643–650.
Doronin K et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 2001; 75: 3314–3324.
Toth K et al. An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated Wnt signaling. Cancer Res 2004; 64: 3638–3644.
Tauber B, Dobner T . Adenovirus early E4 genes in viral oncogenesis. Oncogene 2001; 20: 7847–7854.
Branton P, Roopchand DE . The role of adenovirus E4orf4 protein in viral replication and cell killing. Oncogene 2001; 20: 7855–7865.
Halbert DN, Cutt JR, Shenk T . Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J Virol 1985; 56: 250–257.
Kim N et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011–2015.
Shay JW, Bacchetti S . A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787–791.
Takakura M et al. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 1998; 58: 1558–1561.
Bilsland AE et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 2003; 22: 370–380.
Gu J et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000; 60: 5359–5364.
Gu J et al. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 2002; 21: 4757–4764.
Lin T et al. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 2002; 62: 3620–3625.
Majumdar AS et al. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Therapy 2001; 8: 568–578.
Takeda T et al. Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter. J Clin Endocrinol Metab 2003; 88: 3531–3538.
Huang Q et al. A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res 2004; 10: 1439–1445.
Irving J et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 2004; 11: 174–185.
Kawashima T et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004; 10: 285–292.
Lanson Jr NA et al. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res 2003; 63: 7936–7941.
Wirth T et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003; 63: 3181–3188.
Zou W et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 2004; 23: 457–464.
Kim E et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003; 14: 1415–1428.
Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF . New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 2002; 13: 1737–1750.
Ryan PC et al. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther 2004; 11: 555–569.
Tollefson AE et al. The E3-11.6kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 1996; 220: 152–162.
Tollefson AE et al. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996; 70: 2296–2306.
Doronin K et al. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 2003; 305: 378–387.
Krougliak V, Graham FL . Development of cell lines capable of comlementing E1, E4, and protein IX defective adenvorius type 5 mutants. Human Gene Ther 1995; 6: 1575–1586.
Takakura M et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59: 551–557.
Thimmappaya B, Weinberger C, Schneider RJ, Shenk T . Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell 1982; 31: 543–551.
Doronin K et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the Adenovirus Death Protein. J Virol 2000; 74: 6147–6155.
Tollefson AE, Hermiston TW, Wold WSM . Preparation and titration of CsCl-banded adenovirus stocks. In: Wold NJ (ed). Adenovirus Methods and Protocols. The Humana Press, NJ, 1998, pp 1–9.
Kataoka M et al. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. Cancer Res 1998; 58: 4761–4765.
Kawakami Y et al. A longer human telomerase reverse transcriptase promoter-based conditionally replicative adenovirus shows oncolysis with less toxicity for ovarian cancer treatment. Mol Ther 2004; 9: S235.
McCormick F . Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther 2003; 2: S157–S160.
Nemunaitis J . Selective replicating viral vectors: potential for use in cancer gene therapy. BioDrugs 2003; 17: 251–262.
Jakubczak JL et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003; 63: 1490–1499.
Liu K et al. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc Natl Acad Sci USA 1999; 96: 5147–5152.
Hiyama K et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995; 155: 3711–3715.
Norrback KF, Roos G . Telomeres and telomerase in normal and malignant haematopoietic cells. Eur J Cancer 1997; 33: 774–780.
Harle-Bachor C, Boukamp P . Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci USA 1996; 93: 6476–6481.
Yasumoto S et al. Telomerase activity in normal human epithelial cells. Oncogene 1996; 13: 433–439.
Dmitriev I et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706–9713.
Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A . Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567–2583.
Lichtenstein DL et al. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 2004; 23: 75–111.
Acknowledgements
We thank Dawn Schwartz for help in preparation of the manuscript. This research was supported by Grants CA81829 and CA71704 to WSMW from the National Institutes of Health.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kuppuswamy, M., Spencer, J., Doronin, K. et al. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther 12, 1608–1617 (2005). https://doi.org/10.1038/sj.gt.3302581
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302581
Keywords
This article is cited by
-
Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters
Cancer Gene Therapy (2014)
-
A fully replication-competent adenovirus vector with enhanced oncolytic properties
Cancer Gene Therapy (2010)
-
Verapamil Enhances the Antitumoral Efficacy of Oncolytic Adenoviruses
Molecular Therapy (2010)
-
Expanded Anticancer Therapeutic Window of Hexon-modified Oncolytic Adenovirus
Molecular Therapy (2009)
-
New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster
Cancer Gene Therapy (2009)